Sopharma AD (WAR:SPH) — Market Cap & Net Worth
Market Cap & Net Worth: Sopharma AD (SPH)
Sopharma AD (WAR:SPH) has a market capitalization of $1.52 Billion (zł5.53 Billion) as of September 17, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #7178 globally and #38 in its home market, demonstrating a 10.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sopharma AD's stock price zł10.65 by its total outstanding shares 519255502 (519.26 Million). Also see Sopharma AD total assets for a full breakdown of the balance sheet.
Sopharma AD Market Cap History: 2015 to 2026
Sopharma AD's market capitalization history from 2015 to 2026. Data shows growth from $706.32 Million to $1.52 Billion (8.16% CAGR). Also see Sopharma AD (SPH) cash flow conversion for how efficiently the company converts equity into cash flow.
Sopharma AD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sopharma AD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Sopharma AD stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.82x
Sopharma AD's market cap is 0.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.94x
Sopharma AD's market cap is 22.94 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $706.32 Million | $874.98 Million | $21.31 Million | 0.81x | 33.14x |
| 2016 | $667.77 Million | $877.09 Million | $50.64 Million | 0.76x | 13.19x |
| 2017 | $1.00 Billion | $1.02 Billion | $40.00 Million | 0.98x | 25.00x |
| 2018 | $914.85 Million | $1.18 Billion | $28.34 Million | 0.78x | 32.28x |
| 2019 | $964.08 Million | $1.28 Billion | $86.99 Million | 0.75x | 11.08x |
| 2020 | $1.06 Billion | $1.44 Billion | $29.80 Million | 0.74x | 35.55x |
| 2021 | $1.18 Billion | $1.60 Billion | $89.50 Million | 0.74x | 13.22x |
| 2022 | $1.03 Billion | $1.66 Billion | $71.12 Million | 0.62x | 14.45x |
| 2023 | $1.96 Billion | $1.89 Billion | $95.21 Million | 1.04x | 20.59x |
| 2024 | $1.75 Billion | $2.13 Billion | $76.31 Million | 0.82x | 22.94x |
Competitor Companies of SPH by Market Capitalization
Companies near Sopharma AD in the global market cap rankings as of September 17, 2026. Review tangible equity quality of Sopharma AD to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sopharma AD by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #249 globally with a market cap of $101.38 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #541 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #642 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1204 globally with a market cap of $21.56 Billion USD ( AU$30.48 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #249 | McKesson Corporation | NYSE:MCK | $101.38 Billion | $899.56 |
| #541 | Cencora Inc. | NYSE:COR | $50.53 Billion | $323.29 |
| #642 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $232.65 |
| #1204 | Sigma Healthcare Ltd | AU:SIG | $21.56 Billion | AU$2.64 |
Sopharma AD Historical Marketcap From 2015 to 2026
Between 2015 and today, Sopharma AD's market cap moved from $706.32 Million to $ 1.52 Billion, with a yearly change of 8.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł1.52 Billion | -16.47% |
| 2025 | zł1.82 Billion | +4.08% |
| 2024 | zł1.75 Billion | -10.70% |
| 2023 | zł1.96 Billion | +90.72% |
| 2022 | zł1.03 Billion | -13.14% |
| 2021 | zł1.18 Billion | +11.70% |
| 2020 | zł1.06 Billion | +9.89% |
| 2019 | zł964.08 Million | +5.38% |
| 2018 | zł914.85 Million | -8.52% |
| 2017 | zł1.00 Billion | +49.76% |
| 2016 | zł667.77 Million | -5.46% |
| 2015 | zł706.32 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Sopharma AD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.52 Billion USD |
| MoneyControl | $1.52 Billion USD |
| MarketWatch | $1.52 Billion USD |
| marketcap.company | $1.52 Billion USD |
| Reuters | $1.52 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more